Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Integra LifeSciences (Nasdaq:IART) announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30am ET.
A live webcast of the presentation will be available on the company’s investor relations website under Events & Presentations.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
IART was down 2.31% with mixed peer moves: several names like ESTA (-3.51%) and INMD (-1.52%) were lower, while BBNX gained 6.67%, pointing to stock-specific rather than unified sector action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 08 | Conference appearance | Neutral | +2.6% | Announcement of CFO presentation at BofA 2026 Health Care Conference. |
| May 05 | Leadership change | Positive | +24.1% | Appointment of Stuart M. Essig as CEO and creation of chief commercial officer role. |
| May 05 | Quarterly earnings | Positive | +24.1% | Q1 2026 results with revenue growth and raised adjusted EPS guidance. |
| Apr 20 | Earnings call setup | Neutral | +0.2% | Scheduling of Q1 2026 results release and investor conference call. |
| Apr 07 | Clinical data update | Positive | +0.2% | Presentation plan for new real-world PriMatrix evidence across multiple indications. |
Recent company news, especially leadership and earnings updates, has coincided with strongly positive price reactions, while routine conference or data disclosures saw modest gains.
Over the past few months, Integra LifeSciences has reported several notable developments. On May 5, 2026, Q1 2026 results and raised adjusted EPS guidance coincided with a leadership transition to Stuart Essig as CEO, and the stock moved about 24% higher. Earlier, the company scheduled its Q1 call and shared real-world PriMatrix data, producing small positive reactions. A May BofA conference appearance also saw a modest uptick of about 2.65%. Today’s Jefferies conference notice fits this pattern of ongoing investor-engagement events.
Regulatory & Risk Context
The company has an effective Form S-3ASR shelf registration filed on 2026-02-26, allowing potential future offerings of common stock, preferred stock, debt securities, warrants, purchase contracts and units, with specific terms to be set in later supplements.
Market Pulse Summary
This announcement highlights Integra LifeSciences’ continued outreach to investors, with its CFO presenting at the Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET. It follows recent Q1 2026 results, a CEO transition, and prior conference activity, indicating an active investor-relations cadence. Investors can watch for any commentary during the presentation that builds on the latest financials, strategic priorities, or capital plans under the existing effective S-3ASR registration.
AI-generated analysis. Not financial advice.
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET.
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
Integra LifeSciences Holdings Corporation
